- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Signal Transduction
Volume 2012 (2012), Article ID 210324, 6 pages
Dopamine Receptor-Mediated Heterologous Sensitization of AC5 Requires Signalosome Assembly
1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907-2051, USA
2Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
3Department of Pharmacology Therapeutics, McGill University, McIntyre Medical Sciences Building, Montréal, QC, Canada H3G 1Y6
Received 7 October 2011; Accepted 28 December 2011
Academic Editor: J. Adolfo García-Sáinz
Copyright © 2012 Karin F. K. Ejendal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Chronic dopamine receptor activation is implicated in several central nervous system disorders. Although acute activation of -coupled D2 dopamine receptors inhibits adenylyl cyclase, persistent activation enhances adenylyl cyclase activity, a phenomenon called heterologous sensitization. Previous work revealed a requirement for in D2-induced heterologous sensitization of AC5. To elucidate the mechanism of dependency, we expressed mutants in -deficient cells. Neither -palmitoylation nor -Gβγ interactions were required for sensitization of AC5. Moreover, we found that coexpressing βARKct-CD8 or Sar1(H79G) blocked heterologous sensitization. These studies are consistent with a role for -AC5 interactions in sensitization however, Gβγ appears to have an indirect role in heterologous sensitization of AC5, possibly by promoting proper signalosome assembly.
Dopamine receptors and dopamine signaling have been implicated in various neurological and psychiatric disorders including Parkinson’s disease, schizophrenia, and drug abuse [1–3]. Dopamine receptors are divided into two subfamilies, the Gα s-coupled D1 and D5 receptors and the Gα i/o-coupled D2, D3, and D4 dopamine receptors that have stimulatory and inhibitory effects on adenylyl cyclase (AC), respectively (see  for a recent review). Acute stimulation of D2 dopamine receptors leads to inhibition of AC activity, however, persistent activation of this Gα i/o-coupled receptor paradoxically results in its enhancement . This phenomenon, called heterologous sensitization of AC, is also known as cAMP overshoot, supersensitization, or superactivation of AC. D2 dopamine receptor-induced heterologous sensitization of cyclic AMP signaling has been demonstrated in several cellular systems as well as in animal models and has also been suggested to occur in humans [4–6]. For example, it was observed that repeated administration of the D2 receptor agonist quinpirole enhances AC activity in the caudate putamen, increases CREB phosphorylation, and also alters behavior in rodents [5, 6]. Although this mode of AC regulation has been recognized for over three decades , the molecular signaling mechanism causing heterologous sensitization of AC is only partially understood, attributed to some extent to differences in AC isoform-specific regulation .
There are nine differentially regulated membrane-bound AC isoforms in mammalian cells [4, 8]. Whereas all AC isoforms are stimulated by stimulatory Gα s, only a subset is inhibited by inhibitory Gα i, and some AC isoforms are differentially regulated by Gβγ [4, 8]. Here, we studied human adenylyl cyclase type 5 (AC5) that is potently stimulated by Gα s, inhibited by acute activation of Gα i, and conditionally activated by Gβγ . AC5 is expressed at high levels in the central nervous system and has been identified as a primary effector of D2 dopamine receptors in the striatum [9, 10].
The aim of the current study was to investigate the role(s) of heterotrimeric G proteins in D2 receptor-mediated heterologous sensitization of AC5. By exploring sensitization in cells devoid of endogenous Gα s , we were able to examine the ability of Gα s mutants to support sensitization without interference from endogenous Gα s. Additionally, this Gα s-deficient cellular model expresses very low levels of AC5 making them a reasonable model for studies of recombinant AC5 . Heterologous sensitization of AC5 was readily rescued by wild-type Gα s and by mutants deficient in palmitoylation  or Gβγ interaction . We also assessed the role of Gβγ and the signalosome in D2 receptor-induced heterologous sensitization of AC5 by sequestering Gβγ subunits with βARKct-CD8 [15, 16] and coexpressing a dominant-negative mutant of the Sar1 GTPase . These experiments revealed that both βARKct-CD8 and Sar1(H79G) attenuated sensitization, suggesting that the components of the signaling complex utilized in heterologous sensitization, presumably AC5 and Gα s, assemble postsynthesis in the endoplasmic reticulum (ER). Together with previous findings, the present data support a model in which Gα s directly interacts with AC5. In contrast, Gβγ appears to have an indirect role in heterologous sensitization of AC5.
2. Materials and Methods
The human D2L receptor and AC5 or ΔAC5  were cloned into the dual expression vector pBUDCE4 (Invitrogen, Carlsbad, CA) creating pBUD/hAC5, D2R and pBUD/ΔAC5, D2R. pcDNA3/βARKct-CD8 [15, 16] and pcDNA/vsvg-Sar1 (wild type and H79G)  were used. pcDNA1/Gα s-CFP  was a gift from Dr. Catherine Berlot. The pcDNA3.1/Gα s-IEK+ mutant  was a gift from Dr. Philip Wedegaertner. The C3S mutation was created by site-directed mutagenesis, and the fragment containing the IEK+ mutations was amplified by PCR. The resulting constructs, pcDNA1/Gα s-CFP(C3S) and pcDNA1/Gα s-CFP(IEK+) were sequenced.
2.2. Cell Culture and Transient Transfection
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. Gα s-deficient murine embryonic fibroblast cells, cells [11, 12], were a gift from Dr. Murat Bastepe. Cells were cultured in 50 : 50 mix of F12 : DMEM media supplemented with 5% FBS (HyClone, Logan, UT), 1% Ant-Anti (Invitrogen, Carlsbad, CA) in a humidified incubator at 33°C with 5% CO2. Approximately 80,000 cells/well were seeded in 24-well plates the day before transient transfection. DNA (400 ng pBUD/hAC5 or ΔAC5, D2R alone or in combination with 10 ng pcDNA/Gα s-CFP, 300 ng pcDNA3/βARKct-CD8, or 300 ng pcDNA/vsvg-Sar1) was mixed with Opti-MEM and 1 μL/well Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The medium was replaced with 200 μL/well prewarmed Opti-MEM, and the DNA/Lipofectamine mixture was added to the cells. After 4 hr, culture medium (500 μL/well) was added, and the cells were analyzed after 48 hr. For microscopy, the amount of pcDNA/Gα s-CFP was increased to 100 ng/well.
2.3. Acute cAMP Accumulation
The assays were carried out in assay buffer (EBSS supplemented with 0.2% ascorbic acid, 15 mM HEPES, and 2% BCS (HyClone, Logan, UT), and 500 μM IBMX) with 100 nM forskolin (Tocris Bioscience, Ellisville, MO) as noted for 37°C for 15 min. The media was decanted, ice-cold trichloroacetic acid was added, and the lysates were stored at 4°C. Cyclic AMP was quantified using a competitive binding assay as described previously . Data were collected from a minimum of three independent experiments carried out in duplicate and were normalized to either basal or vehicle conditions. The GraphPad Prism 5 software (GraphPad Software Inc., LaJolla, CA) was used for data and statistical analyses. A value of ≤0.05 was considered statistically significant.
2.4. Heterologous Sensitization
The cells were pretreated with 1 μM quinpirole or vehicle in assay buffer (without IBMX) for 2 hr followed by three washes. cAMP was measured as described above for acute cAMP accumulation, with the addition of 1 μM spiperone to block the action of any residual quinpirole.
Cells were seeded in cover glass slides (Nunc, Rochester, NY). A 12 bit photometric CoolSNAP (Roper Scientific) CCD camera mounted on a TE-2000 inverted epifluorescence microscope (Nikon Instruments Inc., Melville, NY) with filters (ex. 500/20, em. 535/30) from Chroma (Rockingham, VT) was used. Images were acquired with the MetaMorph software (Molecular Devices, Sunnyvale, CA) and analyzed using Image J (http://rsbweb.nih.gov/ij/).
3. Results and Discussion
3.1. Gα s Mutants Rescue Heterologous Sensitization of AC5
Our laboratory has previously shown that mutants of canine AC5 that do not interact with Gα s are deficient in sensitization [23, 24] and that D2-mediated heterologous sensitization of AC5 has an absolute requirement for Gα s . Our present objective was to elucidate the mechanism of Gα s-dependent heterologous sensitization of human AC5 by utilizing two different Gα s-CFP  mutants (Figure 1(a)). The C3S substitution eliminates the N-terminal palmitoylation site, which causes Gα s to mislocalize to the cytosolic fraction . The IEK+ mutant contains a series of substitutions, yielding a Gβγ-binding deficient Gα s that also displays a reduction in palmitoylation .
The Gα s-CFP constructs were coexpressed with AC5 and D2. Since both C3S and IEK+ are deficient in responses to receptor stimulation [13, 21], we used direct stimulation of AC5 with forskolin throughout this study. Basal cAMP accumulation without any Gα s was pmol/well, whereas co-expression of Gα s-CFP increased cAMP accumulation to pmol/well (wild-type, wt), pmol/well (C3S), and pmol/well (IEK+). Forskolin further stimulated cAMP with values 2.5–3-fold over basal levels (Figure 1(b)), indicating that wild-type and both Gα s mutants functionally couple to AC5. Next, expression and subcellular localization of the Gα s-CFP constructs (in the presence of AC5 and D2) were evaluated by fluorescence microscopy (Figure 1(c)). Wild-type Gα s-CFP showed both plasma membrane and intracellular localization, whereas the C3S and IEK+ mutants were predominantly localized intracellularly (Figure 1(c)), consistent with previous reports [14, 21].
To assess whether the Gα s-CFP mutants could rescue heterologous sensitization, cells were pretreated with vehicle or quinpirole followed by cAMP accumulation. Consistent with our previous report , no sensitization of AC5 was observed in the absence of Gα s (Figure 1(d), ctrl). In contrast, coexpression of wild-type Gα s-CFP resulted in robust sensitization of AC5 under both basal and forskolin-stimulated conditions (Figure 1(d)). Surprisingly, expression of the Gα s mutants also significantly rescued heterologous sensitization under basal conditions (white bars) and to a lesser degree forskolin-stimulated conditions (black bars). As both mutants are deficient in palmitoylation and membrane localization, neither palmitoylation per se, nor membrane localization of Gα s appears to be essential for heterologous sensitization of AC5.
3.2. Role of Gβγ Subunits in Heterologous Sensitization of AC5
Although we have established that Gα s is required for heterologous sensitization, our findings above for the IEK+ mutant suggest that direct interactions between Gα s and Gβγ are not critical. This prompted us to further investigate the role of Gβγ in D2 receptor-mediated heterologous sensitization of AC5. The C-terminus of β-adrenergic kinase or GRK2 (βARKct) has been used to sequester Gβγ subunits and inhibit Gβγ-mediated signaling events, including heterologous sensitization [15, 25, 26]. In the absence of βARKct-CD8 (membrane bound βARKct), AC5 displayed robust heterologous sensitization (open bars, Figure 2(a)). Sequestering Gβγ blocked sensitization of AC5, under both basal and forskolin-stimulated conditions, revealing the necessity of Gβγ for heterologous sensitization of AC5 (black bars, Figure 2(a)). In contrast, βARKct-CD8 had no substantial effects on acute D2 receptor activation; quinpirole produced significant inhibition of cAMP accumulation in the presence of βARKct-CD8 (77 ± 10% inhibition; , data not shown). In an effort to explore the site of action for Gβγ-dependent sensitization, we used an N-terminal deletion mutant of AC5, ΔAC5. This mutant is functional and responds to Gα s stimulation but is deficient in binding Gβγ . The ΔAC5 mutant displayed significant sensitization that was also blocked by βARKct-CD8 (Figure 2(b)), suggesting that N-terminal Gβγ binding is not intimately involved in heterologous sensitization of AC5. Instead, there are clearly additional, unidentified Gβγ interaction sites in AC5 that are necessary for heterologous sensitization. Such an assumption is supported by FRET and in vitro activation studies of the AC5 deletion mutant  as well as studies of AC2, which possesses multiple motifs for Gβγ interaction and regulation that are located in the C1b and C2b domains of AC2 . Other possibilities are that ΔAC5 interacts with endogenous AC isoforms in an AC dimer (see ) that binds Gβγ or that specific Gβ and Gγ subunits or Gβγ pairs are involved. However, it is also possible that the Gβγ mechanisms involving sensitization of AC may be indirect .
3.3. Disruption of Signalosome Assembly Affects Heterologous Sensitization of AC5
Because sequestering Gβγ subunits alters signalosome assembly , we hypothesized that a specific signaling complex could be required for heterologous sensitization of AC5. Several small GTPases, including Sar1, are involved in signal complex assembly and anterograde protein trafficking . A series of studies using dominant negative mutants of these GTPases shows that Gα s and Gβγ interact with AC2 during trafficking to the plasma membrane [30, 31] and that the Gα s-AC2 interaction is disrupted by Sar1(H79G) .
To study the possibility that interactions between AC5 and its specific signaling partners play a role, we utilized Sar1 and Sar1(H79G) and noted that coexpression with the dominant negative mutant prevented heterologous sensitization of AC5 (Figure 2(c)). In contrast, acute D2 receptor-mediated inhibition of AC5 was not significantly blocked in the presence of Sar1(H79G) (data not shown). Our data are consistent with the findings that Sar1(H79G) disrupts AC-Gα s interactions (as measured by BRET or coimmunoprecipitation) to a larger degree than AC-Gα i interactions . In contrast, Sar1(H79G) did not affect the interactions between AC and Gβγ , suggesting that the AC interacts with Gβγ at an early step in the endoplasmic reticulum (ER), but that the interaction with Gα s occurs after ER export. The observation that signaling mechanisms of acute activity and heterologous sensitization are differentially affected further supports the hypothesis that heterologous sensitization and acute stimulation are dependent on separate mechanisms and possibly separate signalosome components.
The present data support a complex model of D2 dopamine receptor-induced heterologous sensitization of AC5 where Gα s appears to directly interact with AC5. A role for Gβγ was confirmed; however, our observations suggest an indirect role for Gβγ that may be involved during the formation of the sensitization signaling complex. A critical role for AC5 in mediating dopamine responses has been previously demonstrated in AC5 deficient mice, which show impaired responses to D2 receptor activation . Therefore, these results have implications in brain regions where D2 dopamine receptors and AC5 are coexpressed, such as the striatum , which is implicated in drug addiction, motivation, mood, and voluntary movement. Persistent D2 dopamine receptor activation has also been linked to psychiatric disorders (e.g., schizophrenia and drug abuse) and to the adaptive responses associated with drug therapy in Parkinson’s disease. Enhancing our understanding of the underlying components and mechanisms of heterologous sensitization and regulation of specific AC activity (in the striatum) may aid in the development of improved and future therapies for these disorders. For example, recent studies have identified small molecule inhibitors of Gβγ-mediated signaling  and AC isoform-specific inhibitors  that may offer novel therapeutic strategies for modulating complex CNS behaviors involving dopamine receptor signaling.
|AC :||Adenylyl cyclase|
|cAMP :||Cyclic adenosine monophosphate|
|CFP :||Cyan fluorescent protein|
|D2R :||Dopamine D2L receptor|
|GPCR :||G protein-coupled receptor|
|βARKct :||β-adrenergic kinase c-terminus|
|ER :||Endoplasmic reticulum|
This work was supported by Purdue University and by NIH grants MH060397 (V. J. Watts) and GM60419 (C. W. Dessauer). T. E. Hebért is a Chercheur National of the Fonds de la Recherche en Santé du Québec (FRSQ). The authors would like to thank Dr. Pierre-Alexandre Vidi for help with cloning of constructs. They would also like to thank Jason Conley and Elisabeth Garland-Kuntz for proofreading and making suggestions to improve the present paper.
- S. D. Iversen and L. L. Iversen, “Dopamine: 50 years in perspective,” Trends in Neurosciences, vol. 30, no. 5, pp. 188–193, 2007.
- B. Le Foll, A. Gallo, Y. L. Strat, L. Lu, and P. Gorwood, “Genetics of dopamine receptors and drug addiction: a comprehensive review,” Behavioural Pharmacology, vol. 20, no. 1, pp. 1–17, 2009.
- J.-M. Beaulieu and R. R. Gainetdinov, “The physiology, signaling, and pharmacology of dopamine receptors,” Pharmacological Reviews, vol. 63, no. 1, pp. 182–217, 2011.
- V. J. Watts and K. A. Neve, “Sensitization of adenylate cyclase by Gαi/o-coupled receptors,” Pharmacology and Therapeutics, vol. 106, no. 3, pp. 405–421, 2005.
- J. A. Chester, A. J. Mullins, C. H. Nguyen, V. J. Watts, and R. L. Meisel, “Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters,” Psychopharmacology, vol. 188, no. 1, pp. 53–62, 2006.
- K. E. Culm, A. M. Lim, J. A. Onton, and R. P. Hammer, “Reduced Gi and Go protein function in the rat nucleus accumbens attenuates sensorimotor gating deficits,” Brain Research, vol. 982, no. 1, pp. 12–18, 2003.
- S. K. Sharma, W. A. Klee, and M. Nirenberg, “Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 8, pp. 3092–3096, 1975.
- X. Gao, R. Sadana, C. W. Dessauer, and T. B. Patel, “Conditional stimulation of type V and VI adenylyl cyclases by G protein βγ subunits,” Journal of Biological Chemistry, vol. 282, no. 1, pp. 294–302, 2007.
- K. W. Lee, J. H. Hong, I. Y. Choi et al., “Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase,” Journal of Neuroscience, vol. 22, no. 18, pp. 7931–7940, 2002.
- T. Iwamoto, S. Okumura, K. Iwatsubo et al., “Motor dysfunction in type 5 adenylyl cyclase-null mice,” Journal of Biological Chemistry, vol. 278, no. 19, pp. 16936–16940, 2003.
- M. Bastepe, Y. Gunes, B. Perez-Villamil, J. Hunzelman, L. S. Weinstein, and H. Jüppner, “Receptor-mediated adenylyl cyclase activation through XLαs, the extra-large variant of the stimulatory G protein α-subunit,” Molecular Endocrinology, vol. 16, no. 8, pp. 1912–1919, 2002.
- T. A. Vortherms, C. H. Nguyen, M. Bastepe, H. Jüppner, and V. J. Watts, “D2 dopamine receptor-induced sensitization of adenylyl cyclase type 1 is Gαs independent,” Neuropharmacology, vol. 50, no. 5, pp. 576–584, 2006.
- P. B. Wedegaertner, D. H. Chu, P. T. Wilson, M. J. Levis, and H. R. Bourne, “Palmitoylation is required for signaling functions and membrane attachment of G(q)α and G(s)α,” Journal of Biological Chemistry, vol. 268, no. 33, pp. 25001–25008, 1993.
- D. S. Evanko, M. M. Thiyagarajan, D. P. Siderovski, and P. B. Wedegaertner, “Gβγ isoforms selectively rescue plasma membrane localization and palmitoylation of mutant Gαs and Gαq,” Journal of Biological Chemistry, vol. 276, no. 26, pp. 23945–23953, 2001.
- D. J. Dupré, M. Robitaille, R. V. Rebois, and T. E. Hébert, “The role of Gβγ subunits in the organization, assembly, and function of GPCR signaling complexes,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 31–56, 2009.
- P. Crespo, T. G. Cachero, N. Xu, and J. S. Gutkind, “Dual effect of β-adrenergic receptors on mitogen-activated protein kinase. Evidence for a βγ-dependent activation and a Gα(s)-cAMP-mediated inhibition,” Journal of Biological Chemistry, vol. 270, no. 42, pp. 25259–25265, 1995.
- D. J. Dupré, M. Robitaille, N. Éthier, L. R. Villeneuve, A. M. Mamarbachi, and T. E. Hébert, “Seven transmembrane receptor core signaling complexes are assembled prior to plasma membrane trafficking,” Journal of Biological Chemistry, vol. 281, no. 45, pp. 34561–34573, 2006.
- R. Sadana, N. Dascal, and C. W. Dessauer, “N terminus of type 5 adenylyl cyclase scaffolds Gs heterotrimer,” Molecular Pharmacology, vol. 76, no. 6, pp. 1256–1264, 2009.
- M. Robitaille, N. Ramakrishnan, A. Baragli, and T. E. Hébert, “Intracellular trafficking and assembly of specific Kir3 channel/G protein complexes,” Cellular Signalling, vol. 21, no. 4, pp. 488–501, 2009.
- T. R. Hynes, S. M. Mervine, E. A. Yost, J. L. Sabo, and C. H. Berlot, “Live cell imaging of Gs and the β2-adrenergic receptor demonstrates that both αs and β 1γ7 internalize upon stimulation and exhibit similar trafficking patterns that differ from that of the β2-adrenergic receptor,” Journal of Biological Chemistry, vol. 279, no. 42, pp. 44101–44112, 2004.
- D. S. Evanko, M. M. Thiyagarajan, and P. B. Wedegaertner, “Interaction with Gβγ is required for membrane targeting and palmitoylation of Gα(s) and Gα(q),” Journal of Biological Chemistry, vol. 275, no. 2, pp. 1327–1336, 2000.
- J. A. Przybyla and V. J. Watts, “Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers,” Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 3, pp. 710–719, 2009.
- V. J. Watts, R. Taussig, R. L. Neve, and K. A. Neve, “Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Gαs: characterization of Gαs-insensitive mutants of adenylyl cyclase V,” Molecular Pharmacology, vol. 60, no. 6, pp. 1168–1172, 2001.
- G. Zimmermann, D. Zhou, and R. Taussig, “Genetic selection of mammalian adenylyl cyclases insensitive to stimulation by G(sα),” Journal of Biological Chemistry, vol. 273, no. 12, pp. 6968–6975, 1998.
- C. H. Nguyen and V. J. Watts, “Dexras1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase 1,” Biochemical and Biophysical Research Communications, vol. 332, no. 3, pp. 913–920, 2005.
- T. Avidor-Reiss, I. Nevo, R. Levy, T. Pfeuffer, and Z. Vogel, “Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of G(βγ),” Journal of Biological Chemistry, vol. 271, no. 35, pp. 21309–21315, 1996.
- S. Weitmann, G. Schultz, and C. Kleuss, “Adenylyl cyclase type II domains involved in Gβγ stimulation,” Biochemistry, vol. 40, no. 36, pp. 10853–10858, 2001.
- A. Baragli, M. L. Grieco, P. Trieu, L. R. Villeneuve, and T. E. Hébert, “Heterodimers of adenylyl cyclases 2 and 5 show enhanced functional responses in the presence of Gαs,” Cellular Signalling, vol. 20, no. 3, pp. 480–492, 2008.
- D. J. Dupré and T. E. Hébert, “Biosynthesis and trafficking of seven transmembrane receptor signalling complexes,” Cellular Signalling, vol. 18, no. 10, pp. 1549–1559, 2006.
- D. J. Dupré, A. Baragli, R. V. Rebois, N. Éthier, and T. E. Hébert, “Signalling complexes associated with adenylyl cyclase II are assembled during their biosynthesis,” Cellular Signalling, vol. 19, no. 3, pp. 481–489, 2007.
- R. V. Rebois, M. Robitaille, C. Galés et al., “Heterotrimeric G proteins form stable complexes with adenylyl cyclase and Kir3.1 channels in living cells,” Journal of Cell Science, vol. 119, no. 13, pp. 2807–2818, 2006.
- P. D. Gortari and G. Mengod, “Dopamine D1, D2 and mu-opioid receptors are co-expressed with adenylyl cyclase 5 and phosphodiesterase 7B mRNAs in striatal rat cells,” Brain Research, vol. 1310, pp. 37–45, 2010.
- A. L. Dessal, R. Prades, E. Giralt, and A. V. Smrcka, “Rational design of a selective covalent modifier of G protein βγ subunits,” Molecular Pharmacology, vol. 79, no. 1, pp. 24–33, 2011.
- H. Wang, H. Xu, L. J. Wu et al., “Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain,” Science Translational Medicine, vol. 3, no. 65, article 65ra3, 2011.